ERBB2 and cancer: Since these potential alternative drivers may have the capacity to circumvent HER2 pathway blockade, their widespread presence throughout these HER2 heterogeneous cancers might explain the high level of innate and acquired resistance to HER2‐targeted therapies in breast cancer.